To include your compound in the COVID-19 Resource Center, submit it here.

IMI's innovation ecosystem

How EU's IMI 2 is tackling broader projects with more stakeholders than its prior iteration

The EU's Innovative Medicines Initiative 2 is armed with a bigger war chest than the prior iteration of the public-private partnership - €3.3 billion ($3.5 billion) vs. €2 billion ($2.1 billion) - and has a much wider remit that includes bringing together more types of stakeholders across a broader swath of the innovation ecosystem.

IMI was created in 2008 as a partnership between the European Commission and the European Federation of Pharmaceutical Industries and Associations (EFPIA), and IMI's first phase saw it undertake more than 50 projects that focused on either specific diseases or broad issues such as compound libraries or the use of stem cells for drug discovery. The common thread was that virtually all of the projects were targeted at the early stages of

Read the full 1251 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE